Skip to content

Study · Randomized controlled trial · 1995

5 results

Aprotinin versus desmopressin for patients undergoing operations with cardiopulmonary bypass. A double-blind placebo-controlled study.

Casas JI, Zuazu-Jausoro I, Mateo J, Oliver A, Litvan H, Muñiz-Díaz E, Arís A, Caralps JM, Fontcuberta J

The Journal of thoracic and cardiovascular surgery1 Oct 1995Cited by 40 (Europe PMC)

PMID7475139 (opens in a new tab)DOI10.1016/s0022-5223(05)80180-1 (opens in a new tab)PepBankPUB-07475139
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In cardiopulmonary bypass patients, blood loss was 400 +/- 192 ml/m2 with desmopressin versus 195 +/- 146 ml/m2 with aprotinin.

    In plain wordsIn cardiopulmonary bypass patients, blood loss was greater with desmopressin than with aprotinin.

    Peptide
    Desmopressin
    Outcome
    IncreaseOverall blood loss versus aprotinin
    Study

    n: not reported in source

    Comparator
    Aprotinin
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated

    Measurements

    Difference confidence interval
    98 to 312 ml/m2
    desmopressin versus aprotinin
    Overall blood loss, mean
    400 ml/m2
    desmopressin group
    Overall blood loss, SD
    192 ml/m2
    desmopressin group
    Overall blood loss, mean
    195 ml/m2
    aprotinin group
    Overall blood loss, SD
    146 ml/m2
    aprotinin group

    Source sentences

    Summary
    Overall blood loss was 195 +/- 146 ml/m2 in the aprotinin group, 400 +/- 192 ml/m2 in the desmopressin group, and 489 +/- 361 ml/m2 in the placebo group (95% confidence intervals: difference between desmopressin and aprotinin 98 to 312 ml/m2, p < 0.001;
    2 context sentences
    Summary · context
    We compared aprotinin, desmopressin, and placebo in a double-blind, randomized trial to evaluate bleeding and transfusion requirements.
    Summary · context
    One hundred forty-nine patients (48 received aprotinin, 50 desmopressin, 51 placebo) were included.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In cardiopulmonary bypass patients, blood loss was 400 +/- 192 ml/m2 with desmopressin and 489 +/- 361 ml/m2 with placebo; the abstract reports no test of this difference.

    In plain wordsIn cardiopulmonary bypass patients, blood loss was 400 with desmopressin and 489 with placebo; no test of this difference was reported.

    Peptide
    Desmopressin
    Outcome
    Direction not reportedOverall blood loss versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated

    Measurements

    Overall blood loss, mean
    400 ml/m2
    desmopressin group
    Overall blood loss, SD
    192 ml/m2
    desmopressin group
    Overall blood loss, mean
    489 ml/m2
    placebo group
    Overall blood loss, SD
    361 ml/m2
    placebo group

    Source sentences

    Summary
    Overall blood loss was 195 +/- 146 ml/m2 in the aprotinin group, 400 +/- 192 ml/m2 in the desmopressin group, and 489 +/- 361 ml/m2 in the placebo group
    2 context sentences
    Summary · context
    We compared aprotinin, desmopressin, and placebo in a double-blind, randomized trial to evaluate bleeding and transfusion requirements.
    Summary · context
    One hundred forty-nine patients (48 received aprotinin, 50 desmopressin, 51 placebo) were included.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In cardiopulmonary bypass patients, 66% receiving desmopressin required transfusion versus 26% receiving aprotinin.

    In plain wordsIn cardiopulmonary bypass patients, transfusion was more frequent with desmopressin than with aprotinin.

    Peptide
    Desmopressin
    Outcome
    IncreaseTransfusion proportion versus aprotinin
    Study

    n: not reported in source

    Comparator
    Aprotinin
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated

    Measurements

    Patients given transfusion
    66%
    desmopressin group
    Patients given transfusion
    26%
    aprotinin group

    Source sentences

    Summary
    Twenty-six percent of patients treated with aprotinin, 66% of those treated with desmopressin, and 56% of those treated with placebo were given transfusion
    2 context sentences
    Summary · context
    We compared aprotinin, desmopressin, and placebo in a double-blind, randomized trial to evaluate bleeding and transfusion requirements.
    Summary · context
    One hundred forty-nine patients (48 received aprotinin, 50 desmopressin, 51 placebo) were included.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In cardiopulmonary bypass patients, 66% receiving desmopressin and 56% receiving placebo were given transfusion; the abstract reports no test of this difference.

    In plain wordsIn cardiopulmonary bypass patients, 66% with desmopressin and 56% with placebo were given transfusion; no test of this difference was reported.

    Peptide
    Desmopressin
    Outcome
    Direction not reportedTransfusion proportion versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated

    Measurements

    Patients given transfusion
    66%
    desmopressin group
    Patients given transfusion
    56%
    placebo group

    Source sentences

    Summary
    Twenty-six percent of patients treated with aprotinin, 66% of those treated with desmopressin, and 56% of those treated with placebo were given transfusion
    2 context sentences
    Summary · context
    We compared aprotinin, desmopressin, and placebo in a double-blind, randomized trial to evaluate bleeding and transfusion requirements.
    Summary · context
    One hundred forty-nine patients (48 received aprotinin, 50 desmopressin, 51 placebo) were included.
  5. 05HumanRandomized controlled trialMechanism

    In cardiopulmonary bypass patients, fibrinolytic activation was markedly higher with desmopressin than with aprotinin.

    In plain wordsIn cardiopulmonary bypass patients, clot breakdown activation was higher with desmopressin than with aprotinin.

    Peptide
    Desmopressin
    Outcome
    IncreaseFibrinolytic activation
    Study

    n: not reported in source

    Comparator
    Aprotinin
    Outcome group
    Bleeding and clotting · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Fibrinolytic activation throughout cardiopulmonary bypass was markedly higher with placebo or desmopressin administration.
    3 context sentences
    Summary · context
    This benefit may be explained by a lower activation of fibrinolysis.
    Summary · context
    We compared aprotinin, desmopressin, and placebo in a double-blind, randomized trial to evaluate bleeding and transfusion requirements.
    Summary · context
    One hundred forty-nine patients (48 received aprotinin, 50 desmopressin, 51 placebo) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.